CryoTherapeutics

Executive Summary

CryoTherapeutics is a Belgian medical device company pioneering a novel cryotherapy system for the treatment of coronary artery disease. The company's patented platform consists of a console and an intracoronary balloon catheter that delivers controlled cooling to atherosclerotic plaques. By applying localized cryotherapy, the system aims to stabilize plaques and reduce the risk of rupture, potentially preventing myocardial infarctions. The technology is designed for use by interventional cardiologists under standard X-ray guidance, offering a minimally invasive alternative to current drug-eluting stents or surgical bypass. Founded in 2015 and headquartered in Leuven, Belgium, CryoTherapeutics operates in the cardiovascular and medical devices sectors, targeting a large unmet need in non-stent-based plaque modification. While the company remains in a private, early development stage with limited public financial data, its innovative approach has potential to improve outcomes for millions of patients with vulnerable plaques. The next milestones are expected to include initial clinical feasibility studies and regulatory progression in Europe.

Upcoming Catalysts (preview)

• Q2 2026First-in-human clinical trial results50% success
• Q4 2026CE mark submission for cryotherapy system40% success
• Q3 2026Strategic partnership or licensing deal with a cardiovascular device company30% success